Details

Autor(en) / Beteiligte

• Prinapori, Roberta, MD
• Guinaud, Julie, MD
• Khalil, Antoine, MD
• Lecuyer, Herve, MD, PhD
• Gendrel, Dominique, MD
• Lortholary, Olivier, MD, PhD
• Nassif, Xavier, MD, PhD
• Viscoli, Claudio, MD, PhD
• Zahar, Jean-Ralph, MD, PhD

Titel

Risk associated with a systematic search of extended-spectrum β-lactamase–producing Enterobacteriaceae

Ist Teil von

• American journal of infection control, 2013-03, Vol.41 (3), p.259-260

Ort / Verlag

New York, NY: Mosby, Inc

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• We evaluated 74 children with previous fecal extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae colonization who were hospitalized and receiving a course of antibiotic therapy for suspected infection. Sixty-four patients (86.5%) received a carbapenem agent. Only 3 patients were infected with an ESBL-producing Enterobacteriaceae. Sixty-one (95%) initial antibiotic courses were considered excessive and required deescalation; however, deescalation was accomplished in only 38 patients (62%). This suggests the need for an ESBL control program to decrease carbapenem use and thereby limit carbapenem resistance in gram-negative bacilli.